# Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

> **NCT02605616** · PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 93 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease (NAFLD)
- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** AZ compound
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02605616
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.
- **Last updated:** 2024-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605616, "Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02605616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*